COPD
Chronic obstructive pulmonary disease causing progressive airflow limitation. MSC therapy reduces lung inflammation and supports bronchial tissue repair.
Chronic obstructive pulmonary disease encompasses emphysema and chronic bronchitis — progressive inflammatory lung conditions characterized by irreversible airflow obstruction, destroyed alveolar architecture, and chronic mucus hypersecretion. COPD is the third leading cause of death worldwide and affects over 300 million people.
Tobacco smoke, environmental pollutants, and recurrent infections trigger a self-sustaining cycle of neutrophilic and macrophage-driven inflammation that gradually destroys the lung parenchyma. Standard therapies (bronchodilators, inhaled corticosteroids, supplemental oxygen) manage symptoms but cannot halt or reverse structural lung damage.
Regenerative approaches using MSC therapy represent the most clinically advanced strategy for addressing the inflammatory-fibrotic cycle that drives COPD progression.
When administered intravenously, MSCs home to the pulmonary vasculature, where they release paracrine signals that suppress neutrophilic and macrophage-driven inflammation, reduce matrix metalloproteinase activity responsible for alveolar wall destruction, and promote type II pneumocyte survival and proliferation.
Phase I and II clinical trials have demonstrated the safety and tolerability of MSC infusion in COPD patients, with several trials reporting improvements in FEV1 percentage, 6-minute walk distance, BODE index, and quality-of-life scores. Inflammatory cytokines including TNF-α and IL-8 were reduced in treated patients.
True Regen evaluates COPD patients using spirometry, CT chest imaging, and BODE scoring to determine protocol eligibility and track outcomes at 3, 6, and 12 months post-treatment.
- Stabilization or improvement in FEV1 lung function
- Improved 6-minute walk distance
- Reduced COPD exacerbation frequency
- Lower systemic and pulmonary inflammatory markers
- Improved dyspnea scores and quality of life
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.